Irritable Bowel Syndrome Treatment Market, By Type (Irritable Bowel Syndrome with Constipation, Irritable Bowel Syndrome with Diarrhea, and Mixed Irritable Bowel Syndrome), By Indication (Abdominal Pain, Bloating, Constipation and Diarrhea, Altered Bowel Habits, and Others), By Drug Class (Antispasmodics, Laxatives, Antidiarrheal Medications, 5-HT3 Receptor Antagonists, Guanylate Cyclase-C Agonists, Anticholinergic, Probiotics, Antidepressants, Antibiotics, Dietary Supplements, and Others), By Route of Administration (Oral, Rectal, and Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jan 2025

Code : CMI506

Pages :156

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Irritable Bowel Syndrome Treatment Market Regional Insights

To learn more about this report, Request sample copy

North America Irritable Bowel Syndrome Treatment Market Trends

In 2024, North America is expected to dominate the irritable bowel syndrome treatment market with a 39.3% share, driven by its robust healthcare infrastructure, high patient awareness, and the significant presence of leading pharmaceutical companies in the region. The lucrative growth of the pharmaceutical industry over the years has enabled continuous innovation and development of novel drugs.

Asia Pacific Irritable Bowel Syndrome Treatment Market Trends

The Asia Pacific region is the fastest-growing market for irritable bowel syndrome treatment with a share of 25.7% in 2024, driven by factors such as rising medical tourism, increasing healthcare expenditure, and a growing geriatric population. Countries like India and Thailand attract global patients with affordable, high-quality treatments, while nations like China are significantly boosting healthcare spending to improve access to advanced irritable bowel syndrome therapies.

Irritable Bowel Syndrome Treatment Market Outlook for Key Countries

U.S. Irritable Bowel Syndrome Treatment Market Trends

According to an article updated by NCBI in June 2022, the incidence of inflammatory bowel disease (IBD) in the U.S. ranges from 2.2 to 19.2 cases per 100,000 person-years for ulcerative colitis and 3.1 to 20.2 cases per 100,000 person-years for Crohn's disease (CD). This high prevalence of IBD is anticipated to drive increased demand for Inflammatory Bowel Disease therapeutics during the forecast period.

Canada Irritable Bowel Syndrome Treatment Market Trends

Canada irritable bowel syndrome treatment market is witnessing high growth due to its high irritable bowel syndrome prevalence (affecting 18% of the population), robust healthcare infrastructure, and focus on research and innovation. In April 2022, Health Canada approved Bristol Myers Squibb's ZEPOSIA (ozanimod) capsules for adults with moderately to severely active ulcerative colitis (UC) who did not respond to or were intolerant of conventional or biologic therapies. UC is a chronic inflammatory bowel disease affecting the colon.

China Irritable Bowel Syndrome Treatment Market Trends

The irritable bowel syndrome treatment market in China is projected to experience significant growth due to the aging population and heightened awareness of gastrointestinal health issues. In January 2020, AstraZeneca, in partnership with Ironwood Pharmaceuticals, announced that Linzess (linaclotide), a first-in-class guanylate cyclase-C (GC-C) receptor agonist, has been approved by China’s NMPA for treating adult patients with irritable bowel syndrome with constipation (irritable bowel syndrome-C), providing a vital new treatment option.

Germany Irritable Bowel Syndrome Treatment Market Trends

The growth of the irritable bowel syndrome treatment market in Europe is fueled by awareness campaigns aimed at reducing the stigma around gastrointestinal disorders. Countries like Germany report increased patient engagement in recognizing irritable bowel syndrome symptoms and exploring available treatments. Advanced healthcare systems across the region provide better access to innovative therapies, while ongoing clinical research supports the development of new medications.